G MacLennan
7 Papers
1 Citations
G MacLennan is an academic researcher. The author has contributed to research in topics: Placebo & Medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
SFX-01 in hospitalised patients with community-acquired pneumonia during the COVID19 pandemic: a double-blind, randomised, placebo-controlled trial
Merete Long,Hani Abo-Leyah,Yan Hui Giam,Thenmalar Vadiveloo,Rebecca C Hull,Holly R Keir,Thomas Pembridge,Daniela Alferes,De Lima,Lilia Delgado,Sarah K Inglis,Chloe Hughes,Amy Gilmour,Marek Gierlinski,B. J. New,G MacLennan,Albena T. Dinkova-Kostova,James D. Chalmers +17 more
TL;DR: SFX-01 treatment did not improve clinical status or modulate key Nrf2 targets in patients with CAP primarily due to SARS-CoV-2 infection.
1
A Randomized Double-Blind Placebo-Controlled Trial of Dipeptidyl Peptidase-1 Inhibition in Hospitalized Patients with COVID-19: The STOP-COVID19 Trial
Holy Keir,M. Long,Hani Abo Leyah,Y. Giam,Thenmalar Vadiveloo,Thomas Pembridge,Rebecca C Hull,L. Delgado,Margaret M Band,F. McLaren-Neill,Simon Adamson,E. Lahnsteiner,Aaraon Gilmour,Celia M. Hughes,B. New,D. Connell,R. Dowey,Helena A Turton,Hollie Richardson,D. Cassidy,Arthur J.L. Cooper,Jay Suntharalingam,Lavanya Diwakar,Philip Russell,Jamen Underwood,A. Hicks,D Dosanjh,E. Helene Sage,D C Dhasmana,Michael L. Spears,Rebecca Thompson,Chrostopher Brightling,M. Patel,Jim George,A. Condliffe,Amelia Shoemark,G MacLennan,J. Chalmers +37 more
- 01 May 2022
Stabilised, synthetic sulforaphane in hospitalized patients with suspected COVID-19 pneumonia: a double-blind, placebo-controlled RCT
Hani Abo-Leyah,M. Long,Y. Giam,Thenmalar Vadiveloo,Rebecca C Hull,Holy Keir,Thomas Pembridge,Daniela Alferes de Lima,B. New,S. Inglis,Aaraon Gilmour,C. Hughes,L. Delgado,G MacLennan,Albena T. Dinkova-Kostova,James D. Chalmers +15 more
- 04 Sep 2022
TL;DR: In this article , the authors investigated the efficacy of stabilised sulforaphane, activator of Nrf2, to improve clinical outcomes in patients hospitalized with suspected COVID-19.
Impact of the NRF2 activator, stabilised synthetic sulforaphane, on systemic inflammation in COVID19: results from the STAR-COVID19 trial
M. Long,Y. Giam,Hani Abo-Leyah,Rebecca C Hull,Holy Keir,Thomas Pembridge,Daniela Alferes de Lima,B. New,Suzanne L. Inglis,Thenmalar Vadiveloo,G MacLennan,Aaraon Gilmour,C. Hughes,L. Delgado,Albena T. Dinkova-Kostova,James D. Chalmers +15 more
- 04 Sep 2022
TL;DR: In this paper , a double-blind RCT of stabilised, synthetic sulforaphane (S-SFN)-an Nrf2 inducer-improves clinical status in hospitalised patients with suspected COVID19 pneumonia by curbing the inflammatory response.